Hylander, I agree that the communication has be
Post# of 36566
(Total Views: 367)
Posted On: 03/09/2021 10:49:12 AM
Hylander,
I agree that the communication has been far from stellar. So many questions, so little answers. But, I am will to wait until next week. Why, because both NGIO and GNBT 10-Qs are due out. Granted, that will only cover up to Jan 31, 2021, but it will be at least something and information on all the “stuff” that NGIO has been doing that is not Covid related. Plus, on Sunday 3/14, the 180 day period from the 9/14 S-1 (IPO info) will be up. I really don’t understand what the time period is all about, but I hope that it is significant enough that all this hush hush no NGIO info can now be discussed. So, if there is no PR next week, then I believe we are justified in making a ruckus.
I got a message from TDA. It was:
“Thank you for contacting TD Ameritrade and allowing me to assist you with your inquiry.
This is the correct ticker symbol for Nugenerex Immuno Oncology Inc, when the company went through the reorganization to update the ticker symbol, this is the symbol (NUGX) they authorized for these shares. At this time we do not have any additional information, but you can try to contact Nugenerex Immuno Oncology Inc investor relations for additional information.”
So, this is looking like what I previously posted https://investorshangout.com/post/view?id=6075957 that NUGX is a special dividend moniker for our NGIO shares. The Gray Sheet info would make sense, since we were given (trade) these share before the IPO has gone into effect. So, there is one more BIG question that needs answered. How and when will these NUGX shares be converted into NGIO shares. When NGIO becomes actively traded on NASDAQ? Before the IPO? During the IPO? After the IPO? How long after the IPO? Will 1 NUGX share = 1 NGIO share or some other ratio? This opens a plethora of questions that need a response. I am thinking a PR won’t be enough for answers. A working CC is probably needed.
I agree that the communication has been far from stellar. So many questions, so little answers. But, I am will to wait until next week. Why, because both NGIO and GNBT 10-Qs are due out. Granted, that will only cover up to Jan 31, 2021, but it will be at least something and information on all the “stuff” that NGIO has been doing that is not Covid related. Plus, on Sunday 3/14, the 180 day period from the 9/14 S-1 (IPO info) will be up. I really don’t understand what the time period is all about, but I hope that it is significant enough that all this hush hush no NGIO info can now be discussed. So, if there is no PR next week, then I believe we are justified in making a ruckus.
I got a message from TDA. It was:
“Thank you for contacting TD Ameritrade and allowing me to assist you with your inquiry.
This is the correct ticker symbol for Nugenerex Immuno Oncology Inc, when the company went through the reorganization to update the ticker symbol, this is the symbol (NUGX) they authorized for these shares. At this time we do not have any additional information, but you can try to contact Nugenerex Immuno Oncology Inc investor relations for additional information.”
So, this is looking like what I previously posted https://investorshangout.com/post/view?id=6075957 that NUGX is a special dividend moniker for our NGIO shares. The Gray Sheet info would make sense, since we were given (trade) these share before the IPO has gone into effect. So, there is one more BIG question that needs answered. How and when will these NUGX shares be converted into NGIO shares. When NGIO becomes actively traded on NASDAQ? Before the IPO? During the IPO? After the IPO? How long after the IPO? Will 1 NUGX share = 1 NGIO share or some other ratio? This opens a plethora of questions that need a response. I am thinking a PR won’t be enough for answers. A working CC is probably needed.
(3)
(0)